Read + Share
Lawrence L. TROP2-targeted ADCs demonstrate survival benefit for patients with advanced
triple-negative breast cancer: Almost a 3-month improvement was seen in median
PFS for patients assigned to sacituzumab govitecan in comparison to those
assigned to chemothera Cancer 2026;132:e70249.
PMID: 41712613
|
 |
|
